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ABSTRACT 
Streptococcus pneumoniae is responsible for severe infections, causing millions of deaths yearly. 
Immunoglobulin G (IgG) antibodies against the capsular polysaccharide (CPS) offer S. pneumoniae 
serotype-specific protection. In this work, we examined the applicability of the microarray technology 
to detect CPS type-specific IgGs in serum, using a collection of 22 microarray-printed S. pneumoniae 
CPSs. First, printing of five CPSs onto nitrocellulose-coated glass slides was tested. Successful 
printing was only achieved for certain CPS types and concentrations. This behavior was tentatively 
related with diverse viscosities of the CPS solutions. Measurement of dynamic viscosities fully 
supported this assumption and helped to establish suitable CPS type- and concentration-dependent 
printing conditions. Next, the potential of CPS microarrays for detecting recognition by anti-CPS IgGs 
was examined using well-defined rabbit pneumococcal antisera. In all cases, the expected antiserum–
CPS binding signals were detected, prompting a proof-of-concept analysis of human serum samples. 
Clearly distinct serum- and CPS-specific binding patterns and intensities were observed, evidencing 
selective detection of CPS type-specific IgGs. Compared to the ELISA assay commonly used to 
quantitate CPS type-specific IgGs in serum, the newly developed S. pneumoniae CPS microarrays 
offer the advantage of enabling the simultaneous analysis of multiple CPS–serum interactions using 
minute CPS amounts and significantly reduced serum volumes. Therefore, the approach could be 
particularly valuable for gauging the presence of CPS type-specific IgGs in human serum when 
sample volumes are limited and/or numerous serum samples are being examined. 
  
 
Streptococcus pneumoniae, a Gram-positive bacterium that asymptomatically colonizes the human 
upper respiratory tract, can also cause severe infectious diseases, like acute otitis media, pneumonia, 
meningitis, and septicemia,
1
 being responsible for millions of deaths each year with special incidence 
among children < 2 years old, adults ≥ 65 years of age, and patients with high-risk conditions. As an 
example, a systematic analysis covering 195 countries during the period 1990–2016 revealed that S. 
pneumoniae was the leading cause of lower respiratory infection morbidity and mortality worldwide, 
accounting in 2016 for more deaths than all other aetiologies combined.
2
 Moreover, despite 
vaccination programs, the incidence of invasive pneumococcal disease remains high.
3
 An important 
contributor to S. pneumoniae virulence is its polysaccharidic capsule. To date, at least 99 different 
serotypes, divided into 25 individual types and 21 serogroups, each composed of two to eight 
serotypes with related capsular antigenic determinants, have been identified.
4,5
 The capsule prevents 
complement activation and phagocytosis by shielding inner bacterial surface structures, and thereby 
plays a key role in the bacterial defense against the host innate immune system.
4
 On the other hand, 
binding to S. pneumoniae cells of serum immunoglobulin G (IgG) antibodies against the capsular 
polysaccharide (CPS) leads to opsonization and rapid clearance of the bacterium. However, this 
protection is strictly CPS type-specific. Therefore, current pneumococcal vaccines use as immunogens 
those CPSs most frequently associated with severe disease. 
In 2000, the World Health Organization (WHO) selected a well-characterized enzyme-linked 
immunosorbent assay (ELISA) protocol for quantitation in human serum of IgG antibodies specific for 
S. pneumoniae CPSs, particularly in response to pneumococcal vaccines.
6
 The protocol involved 
coating microtiter plate wells with individual S. pneumoniae CPSs and detection of serum anti-CPS 
IgGs bound to each well by incubation with anti-human IgG antibody conjugated with alkaline 
phosphatase, followed by addition of p-nitrophenyl phosphate and measurement of the yellow end 
product, p-nitrophenol. A main disadvantage of this and other ELISA plate-binding assays is that they 
require relatively large amounts of CPS/serum samples and only one CPSserum pair is examined per 
well. As an alternative, the microarray technology enables the simultaneous analysis of a large number 
of interactions using very small amounts of sample. This technology has been successfully used to 
explore bacterial surface glycans and their interactions with diverse glycan-binding proteins.
7–10
 
Moreover, microarrays incorporating bacterial carbohydrate structures have proved to be useful for 
serodiagnosis of bacterial infections, identification of antigenic determinants for vaccine development, 
and mapping of epitopes recognized by bacteria-specific anti-carbohydrate antibodies.
10
 Although 
non-covalent printing was originally proposed for preventing alteration of carbohydrate epitopes,
11
 the 
strategy typically used for immobilization of bacterial carbohydrates involved chemical conjugation to 
derivatized slide surfaces.
10
 The panel of structures printed in the arrays ranged from large collections 
of diverse bacterial glycans, including CPSs from some bacterial species and strains, to more focused 
libraries of a specific glycan type or bacterial origin. In the case of S. pneumoniae, a series of 
microarrays containing the CPS of a particular serotype and small synthetic substructures thereof have 
been used for deciphering antigenic determinants in the search of vaccine candidates.
1216
 However, to 
the best of our knowledge, a focused array including a collection of CPSs from different S. 
pneumoniae serotypes has not been developed so far.  
In this work, we evaluated the potential applicability of the microarray technology to detect S. 
pneumoniae type-specific antibodies in human serum using a repertoire of microarray-printed S. 
pneumoniae CPSs. The collection of CPSs in the arrays comprised 21 different polysaccharides 
included in the pneumococcal polysaccharide vaccine PPSV23 (Pneumovax
®
), which is currently 
licensed worldwide for those aged ≥ 2 years, plus one polysaccharide (serotype 6A) not included in 
this vaccine but found to be responsible for causing pneumococcal disease in USA and/or EU in the 
last ten years. First, the challenge of generating microarrays displaying uniform non-covalent printing 
of these CPSs was addressed. The diverse viscosities of the CPS solutions made necessary the 
establishment of printing conditions in a CPS type- and concentration-dependent basis. Next, binding 
and competition assays using well-defined rabbit pneumococcal antisera against particular CPS 
serotypes printed in the array served to prove the specificity of the assay. Finally, serum samples from 
pneumonia patients were examined. The results supported the utility of S. pneumoniae CPS 
microarrays for selectively detecting CPS type-specific IgGs in human sera. 
 
EXPERIMENTAL SECTION 
Materials. Pneumococcal CPSs of serotypes (Danish nomenclature) 1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 
10A, 11A, 12F, 14, 15B, 17F, 19A, 19F, 20, 22F, 23F, and 33F, all of them included in the 23-valent 
vaccine, as well as serotype 6A CPS, were purchased from the American Type Culture Collection 
(ATCC). CPSs that are underlined are also included in the currently licensed 13-valent pneumococcal 
conjugate vaccine (PCV13). The candidate 15-valent PCV contains those serotypes included in 
PCV13 plus serotypes 22F and 33F, and is currently under clinical evaluation.
17,18
 Rabbit pool sera 
against S. pneumoniae CPSs types 3, 4, and groups 9, 12 (pool R), against CPSs types 5, 8, and groups 
10, 15, 17 (pool S), and against CPSs types 2, 20, and groups 11, 22, 33 (pool T) were from Statens 
Serum Institut (SSI Diagnostica). Group serum against S. pneumoniae CPSs 19F, 19A, 19B, and 19C 
(designated group serum 19) and type serum against S. pneumoniae type 1 (type serum 1) were also 
from SSI Diagnostica. Sera from patients with pneumonia of diverse bacterial aetiology were collected 
at the Hospital Universitari Germans Trias I Pujol following the ethical principles of the Declaration 
of Helsinki (Fortaleza 2013), the Standards of Good Clinical Practice, the legislation on biomedical 
research (Law14/2007) and biobanks (RD1716/2011). Samples and databases were coded to keep 
patients’ anonymity and privacy following the Spanish legal normative (LOPD 15/1999 and RD 
1720/2007) and the European General Data Protection Regulation. 
Microarray Preparation. Dynamic viscosities of 1 mg/mL CPS solutions in milli-Q water and/or 
printing solution (47% glycerol and 0.06% (v/v) Triton X-100) were measured at 25 C with a 
Kinexus Ultra+ rheometer (Malvern Panalytical), using parallel plate geometry of diameter 40 mm 
(PU40), 0.1 mm gap and 0.5 Pa shear stress. CPS solutions at 3 mg/ml in milli-Q water were used to 
prepare serial dilutions, from 0.1 to 0.01 mg/mL, in printing solution, diluted printing solution, or 
milli-Q water, as required to keep for each CPS and concentration the viscosity in a range suitable for 
printing. The Cy3 fluorophore (GE Healthcare) was added to these dilutions at a final concentration of 
1 μg/mL. All solutions were printed as triplicates on 16-pad nitrocellulose-coated glass slides (Grace 
Biolabs ONCYTE NOVA) using a noncontact arrayer (Sprint, Arrayjet Ltd.). Immediately before 
printing, samples were gently centrifuged (200g for 1 min) to avoid the presence of bubbles, which 
would cause problems in sample aspiration, and of undesired particles that could block the 
microarrayer capillaries.
19
 Printed slides were scanned to monitor spot location and grid Cy3 signals 
(excitation at 532 nm, green laser) using a GenePix Autoloader 4200AL (Axon Instruments) 
microarray scanner. The slides can be stored at room temperature in a dry and dark place, and remain 
stable for at least 1 year. 
Microarray binding and competition assays. Before the binding/competition assays, 1 μL-
samples of rabbit pneumococcal antisera were diluted in 100 µL (400 µL in the case of type serum 1) 
of an absorption buffer composed of 5 mM sodium phosphate, pH 7.2, 0.2 M NaCl (PBS), 0.1% (v/v) 
Tween 20, 1% bovine serum albumin (BSA), and 10 µg/mL of a 1:1 mixture of pneumococcal cell 
wall polysaccharides CWPS and CWPS2 (CWPS Multi, SSI Diagnostica), and incubated for 1 h at 20 
C. In competition experiments, 25 µg/mL of the appropriate CPS was added to this absorption buffer. 
Human sera were processed similarly,  1 μL-samples being diluted in 100 μL of absorption buffer. 
Pre-absorption of CWPSs-specific antibodies (step also included in the WHO ELISA protocol) is 
essential to minimize non-CPS-specific binding signals, as CWPSs are commonly expressed by 
pneumococci and expected to be present in purified CPSs, and most people have antibodies targeting 
CWPS, possibly in response to pneumococcal carriage.
6 
To test the binding of sera to the microarrays, these were first blocked for 1 h with 0.25% Tween 
20 and 1% BSA in PBS. Then, slides were washed once with PBS and incubated for 90 min with 100 
μL per pad of pre-absorbed serum samples. To exclude a direct binding to the CPSs of the secondary 
antibodies and/or streptavidin, subsequently used for detection, blank assays by incubation with 100 
μL of absorption buffer, instead of sera, were run in parallel. After four short rinses with PBS, slides 
were incubated for 1 h with a 1:1000 dilution in absorption buffer of biotin-labeled goat anti-rabbit 
(Dako) or anti-human IgGs (Vector Laboratories), as appropriate. After four further washes with PBS, 
slides were incubated for 35 min in the dark with AlexaFluor-647 (AF647)-labeled streptavidin 
(Invitrogen) at 1 μg/mL in PBS containing 0.1% Tween 20. All incubation steps took place at 20 C 
and protected from dust. Finally, slides were thoroughly washed with PBS and milli-Q water, drained, 
let dry, and scanned for AF647 fluorescence signals red (excitation at 635 nm, red laser), using a 
GenePix Autoloader 4200AL microarray scanner. The signals were quantified with the GenePix Pro 
6.1 software (Molecular Devices). For spot segmentation, a fixed 100-μm diameter circle and the grid 
of Cy3 signals as reference for spot coordinates were employed. Median spot intensities minus median 
local background were used for final quantitation. 
 
RESULTS AND DISCUSSION 
Preparation of CPS microarrays. Different microarray surfaces can be used for printing samples 
of interest (the probes) to be evaluated for recognition by relevant targets. Among these surfaces, 
nitrocellulose-coated slides have proved to be very useful for straightforward adsorption of a variety of 
probes, spanning from purified biomolecules to entire cells. The ELISA protocol designated by the 
WHO as reference assay for quantitation in human serum of anti-S. pneumoniae CPS IgGs is based on 
adsorption of CPSs on microtiter plate wells. Therefore, nitrocellulose-coated slides were selected for 
the preparation of microarrays of purified S. pneumoniae CPSs. Printing on this surface should avoid 
damaging the nitrocellulose membrane with the microarrayer dispensing capillaries, what could lead to 
errors in the quantitation of spot intensities. Therefore, the use of a non-contact microarray printer is 
indicated. The successful performance of this type of printers crucially depends on the viscosity of 
probe solutions, as sample droplets are ejected from printing nozzles over the slide surface, traveling a 
short distance through the air. For printing using the Arrayjet Sprint non-contact arrayer, used in this 
work, probe solutions are routinely prepared in the recommended printing solution that contains 47% 
glycerol, what in principle should ensure an appropriate viscosity for uniform printing. Triton X-100 is 
also included in the printing solution to ensure the cleanliness of the system. To examine the 
applicability of this set up for printing CPS solutions, we first tested the behaviour of five CPSs, 
namely 1, 3, 6A, 6B, and 19A at 1 to 0.03 mg/mL in printing solution. Disappointingly, successful 
printing was only achieved for CPS 19A at 0.1 mg/mL and below, and for CPSs 1 and 6A at 0.03 
mg/mL, while for CPSs 3 and 6B printing failed even at the lowest concentration. Moreover, several 
sample loading capillaries of the microarrayer were clogged up with the solutions, pointing at an 
exceedingly high viscosity (please note that, before printing, samples were centrifuged to avoid the 
presence of undesired particles that could obstruct the capillaries). Therefore, CPS solutions in 
different dilutions of printing solution were next tested. Again, successful printing was only observed 
for certain combinations of CPS concentration and printing solution dilution, evidencing that printing 
conditions should be established in a CPS type- and concentration-dependent basis. A possible 
explanation for this behavior was that CPS solutions themselves could exhibit very diverse viscosities, 
due to their different chemical structure and size. Therefore, dynamic viscosities of solutions in 
printing solution of all CPSs to be included in the arrays were determined. 
As compiled in Table 1, there were obvious differences in viscosity among 1 mg/mL CPS solutions 
in printing solution, ranging from 3.3 to 46.8 cP. Of note, the printing performance observed for the 
five CPSs used in the initial tests entirely correlated with their viscosities, as CPS 19A showed the 
lowest viscosity (5.4 cP), followed by CPSs 6A and 1 (6.6 and 9.45 cP, respectively), while for CPSs 3 
and 6B, whose printing failed even at a concentration of 0.03 mg/mL, measured viscosities were 
significantly higher (27–28 cP). To help in the establishment of appropriate printing conditions, 
measurements in milli-Q water for those CPSs exhibiting the highest viscosities were also performed 
(Table 1). Based on the values obtained, different percentages of printing solution were tested for each 
CPS type and concentration. The best conditions are given in Table 1. Please note that although most 
CPSs could be successfully printed at a concentration of 0.3 mg/mL when the appropriate percentage 
of printing solution was used, only 0.1 to 0.01 mg/mL dilutions were finally used for assembling the 
CPS microarrays. The aim was to facilitate a straightforward comparison of the signals observed for 
the different array-printed CPSs in binding assays with rabbit pneumococcal antisera and human 
serum samples. 
  
Table 1. Dynamic viscosity of pneumococcal CPS solutions 
and percentage of printing solution used for microarray 





Percentage of printing 
solution used for 0.1–0.01 
mg/mL CPS dilutions 
0.1  0.03  0.01  
 PS
a 
3.5    
 water 0.8    
1  PS 9.45 70% 100% 100% 
2  PS 3.5 70% 100% 100% 




50% 70% 70% 
4  PS 11.1 70% 70% 100% 
5  PS 7.2 70% 100% 100% 




100% 100% 100% 




50% 70% 70% 




30% 50% 70% 
9N PS 15 70% 70% 100% 




30% 50% 70% 
10A  PS 6 100% 100% 100% 
11A PS 9.7 70% 100% 100% 
12F  PS 4.4 100% 100% 100% 
14  PS 6.3 100% 100% 100% 
15B  PS 7.2 70% 100% 100% 
17F PS 5.6 100% 100% 100% 
19A PS 5.4 100% 100% 100% 
19F PS 8.3 70% 100% 100% 
20  PS 9.3 70% 100% 100% 
22F  PS 10.4 50% 70% 100% 




30% 50% 70% 
33F  PS 3.3 100% 100% 100% 
a




Binding of rabbit pneumococcal antisera to microarray-printed CPSs. The potential of the 
established CPS microarrays for detecting recognition by anti-pneumococcal CPS IgGs was first 
examined by testing the binding of five well-defined rabbit pneumococcal antisera against particular 
CPS serotypes printed in the array, namely, pool serum R (expected to recognize serotypes 3, 4, 9N, 
9N, and 12F), pool serum S (expected to recognize serotypes 5, 8, 10A, 15B, and 17F), pool serum T 
(expected to recognize serotypes 2, 11A, 20, 22F, and 33F), group serum 19 (expected to recognize 
serotypes 19A and 19F), and type serum 1. As shown in Figure 1, serum-specific binding patterns 
were observed, and the fluorescence intensity of the binding signals correlated with the array-printed 
concentration of the recognized CPS(s), evidencing CPS- and dose-dependent responses. Worth 
mentioning, the observation of dose-dependent responses is crucial to discern between meaningful and 
irrelevant fluorescent signals. Thus, detection of serum binding to only one particular CPS dilution is 
indicative of an artefact, as e.g., contamination. An example is the spurious binding of pool serum T to 
one dilution of CPS 10A (Figure 1C–D and M, N), although this serum does not contain anti-CPS 10 
IgGs. 
To further examine the specificity of antisera binding signals, competition assays were carried out 
in the presence of selected CPSs in solution. In detail, CPSs used in these experiments were: i) CPS 1 
for competition assays with type serum 1, ii) CPSs 19A and 19F for group serum 19, iii) CPSs 3 and 4 
for pool serum R, iv) CPSs 5 and 8 for pool S, and v) CPSs 2 and 20 for pool T. The presence of these 
CPSs significantly reduced or even abolished antisera binding to the corresponding array-printed CPS 
(Figure 1), confirming the serotype specificity of the respective IgG antibodies. Altogether, these 
assays proved the efficiency of the established CPS-based microarray set-up for detecting binding of 
serotype-specific anti-pneumococcal antibodies in rabbit antisera. Therefore, its usefulness for 





Figure 1. Binding of rabbit pneumococcal antisera to microarray-printed CPSs. CPSs were printed as 
triplicates at three different concentrations (0.1, 0.03, and 0.01 mg/mL), and the binding of antisera in 
the absence or presence of selected CPSs in solution was detected using AF647-labelled streptavidin 
as final step, as described in the Experimental Section. (A) CPS printing layout. (B–E) Representative 
images of fluorescent signals observed for the binding of type serum 1 (B) and of pool serum T in the 
absence (C) or presence of CPS 2 (D) or CPS 20 (E). (F–N) Plot of fluorescence intensities for the 
binding of type serum 1 /+ CPS 1 (F), group serum 19 /+ CPS 19A (G) or 19F (H), pool serum R 
/+ CPS 3 (I) or 4 (J), pool S /+ CPS 5 (K) or 8 (L), and pool T /+ CPS 2 (M) or 20 (N). 
Fluorescence intensities in the absence of CPSs in solution are represented by filled columns, while 
those from competition assays are represented by crosshatched columns. Data shown correspond to the 
mean of triplicate spots and error bars indicate the standard deviation of the mean. 
 
 
Detection of CPS-specific IgGs in human serum samples. Randomly selected serum samples 
from patients with pneumonia of diverse bacterial aetiology, i.e., S. pneumoniae (samples Sp1–3), 
Haemophilus influenzae (sample Hi), Legionella pneumophila (sample Lp), or suspected (because the 
bacterium was only isolated from a respiratory sample) S. pneumoniae aetiology (sample sSp) were 
used for a proof-of-concept study. Binding signals were obtained for all the samples, although the 
binding patterns and fluorescent intensities were clearly distinct (Table 2). As an example, strong 
dose-dependent binding of serum Sp1 to many microarray-printed CPSs was observed, whereas the 
binding of serum Sp4 was much more selective. Anti-pneumococcal CPS IgGs were also detected in 
samples from patients with H. influenzae, L. pneumophila, or suspected S. pneumoniae pneumonia, 
although again different binding profiles and intensities were evident (Table 2). A thorough analysis of 
the results clearly goes beyond the scope of this work. Still, it is interesting to mention the detection in 
all the samples tested of antibodies against CPS 14, one of the most common S. pneumoniae serotypes 
worldwide before the introduction of pneumococcal conjugate vaccines. Competition assays carried 
out with sample sSp in the presence of CPS 14 in solution confirmed the specificity in the recognition, 
as the binding signals to printed CPS 14 were completely abolished. In striking contrast, significant 
binding to CPSs 4, 12F, and 22F was only detected for serum Sp1, and the same was found for CPS 
19F and Sp3. Furthermore, no significant binding signals were detected for CPSs 5 and 6A for any of 
the serum samples tested (please note that CPS 5 was found to be recognized by the appropriate rabbit 
antiserum, proving its availability in the array for IgG recognition). Therefore, the results supported 




Table 2. Binding intensities of human serum samples to 
microarray-printed S. pneumoniae CPSs  
CPS 
Serum samples 
Sp1 Sp2 Sp3 Sp4 sSp Hi Lp 
Maximum fluorescence intensity
a





















1  +++ ∙ ++ ∙ ∙ ++ ∙ 
2  +++ + + + + ∙ ++ 
3  + + + +++ ∙ ∙ ∙ 
4  + ∙ ∙ ∙ ∙ ∙ ∙ 
5  ∙ ∙ ∙ ∙ ∙ ∙ ∙ 
6A  ∙ ∙ ∙ ∙ ∙ ∙ ∙ 
6B  ++ ∙ ∙ ∙ ∙ +++ ∙ 
8  ++ ∙ + ∙ ∙ ∙ ++ 
9N + + + ∙ + ∙ + 
9V  + ++ + ∙ ∙ ∙ + 
10A  ++ + ++ ∙ + ∙ + 
11A ++ ∙ ++ ∙ + ∙ ++ 
12F  + ∙ ∙ ∙ ∙ ∙ ∙ 
14  ++ + +++ + +++ +++ ++ 
15B  ∙ + ∙ ∙ ++ ∙ +++ 
17F + + ∙ ∙ ∙ ∙ + 
19A ++ ++ ∙ ∙ ∙ ∙ ∙ 
19F ∙ ∙ + ∙ ∙ ∙ ∙ 
20  ++ ∙ ∙ ∙ + + ++ 
22F  + ∙ ∙ ∙ ∙ ∙ ∙ 
23F  ++ + ∙ ∙ ++ ∙ ∙ 
33F  +++ +++ + ∙ +++ ∙ +++ 
a
 Maximum fluorescence intensity (in relative fluorescent 
units, rfu) observed for the binding to a 0.1 mg/mL CPS 
dilution printed in the array. 
b
 Percent binding intensities 
taking as 100% the maximum fluorescence intensity: +++ ≥ 
60%; ++ > 30%; + > 10%; ∙ < 10%.  
  
CONCLUSIONS 
The microarray technology is a versatile tool for high-throughput analysis of molecular interactions 
and identification of binding partners. Consistent and uniform printing of relevant samples in the 
arrays at comparable concentrations is critical for obtaining reliable information. In this work, we 
developed a strategy for non-covalent printing of a collection of S. pneumoniae CPSs. It involves 
measurement of the viscosity of CPS solutions and adjustment of printing conditions, based on the 
measured viscosities, in a CPS type- and concentration-dependent manner. This strategy, which could 
also be exploited for non-contact printing of other samples with high viscosity, enabled the 
establishment of a microarray set-up for detecting binding of serotype-specific anti-pneumococcal 
antibodies. 
The ELISA assay selected by the WHO for quantitation in human serum of IgG antibodies specific 
for S. pneumoniae CPSs involves the adsorption of CPSs onto microtiter plate wells, generally using 
100 μL per well of CPS solutions at 1–10 μg/mL (0.1–1 μg per well), incubation of each well with 50 
μL of serially diluted serum, and subsequent detection of bound antibodies by incubation with alkaline 
phosphatase-conjugated anti-human IgG followed by addition of an alkaline phosphatase substrate and 
colorimetric quantitation of the enzyme product developed.
6
 The pilot study here presented put 
forward the possibility of using CPS-based microarrays for this purpose. A main advantage is the 
requirement of much smaller amounts of CPSs for testing a given serum dilution. As the microarrayer 
used in the present study dispenses 100 pL of CPS solution per spot, the amount of printed CPS at 
the highest concentration here used was 10 pg, that is, 4 orders of magnitude smaller than the 
minimum amount recommended for coating each microtiter plate well in the ELISA assay. The 
volume of serum dilution used was also substantially smaller, as 100 μL were sufficient for examining 
the presence of antibodies against all the CPS types included in the array, in our case 22 CPSs printed 
as triplicates at three different concentrations. Of note, the possibility of comparing binding signals to 
different amounts of printed CPS facilitates the detection of false positives, which are easily spotted 
when dose-dependent responses are not observed. Thus, multiple CPS–serum interactions are 
simultaneously examined in a single microarray pad, as opposed to the ELISA assay in which only 
one CPSserum pair is examined per well. All things considered, the use of CPS-microarrays for 
measuring S. pneumoniae serotype specific IgGs in human serum could be an alternative (or 
complement) to the ELISA assay, calling for a detailed quantitative analysis using quality control and 
reference standard sera. At any rate, the semi-quantitative study reported here demonstrates the utility 
of the approach for gauging the presence of CPS type-specific IgGs in serum, what could be 
particularly valuable when sample volumes are limited and/or in studies involving numerous serum 
samples, e.g. for determination of serotype-specific contributions to current pneumococcal diseases or 
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